Loading
A phase 2 trial of an investigational treatment in advanced solid tumours, run by Abscint NV/SA, now recruiting.
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 is a phase 2 interventional study registered as NCT06369831 by Abscint NV/SA, with 60 participants planned, started 2024-09-12 and due to reach its primary completion in 2026-09.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PET (positron emission tomography), PET/CT, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
Shares HER2 PET and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/